Abstract��OBJECTIVE To establish quality control methods for recombinant anti-EBOV mAbs which are comprised by three anti-EBOV glycoprotein mAbs. METHODS The binding-activity of recombinant humanized anti-EBOV mAbs to EBOV glycoprotein was evaluated by ELISA.Peptide map by LC-MS was used in the identification tests. Purity was analyzed by CE-SDS and SEC-HPLC. iCIEF was performed to measure the PI value and the charge heterogeneity. 2AB was labeled on the released glycan, and was analyzed by NP-HPLC and mass spectrometry. The concentration of polysorbate 20 was tested by HPLC. RESULTS The EC50s of recombinant anti-EBOV mAbs were (12.53��1.62), (11.10��0.62) and (6.09��0.35) ng��mL-1, respectively. The theoretical sequence coverage rates of three mAbs were all above 95%. The main peak area percentages shown by non-reduced CE-SDS were (94.41��0.05)%, (95.58��0.17)% and (96.11��0.05)%. The peak area percentages of both heavy and light chain shown by reduced CE-SDS were (98.19��0.06)%, (97.97��0.03)% and (98.57��0.03)%. The main peak area percentages shown by SE-HPLC were (99.59��0.01)%, (99.56��0.01)% and (99.74��0.01)%. The isoelectric points of the main peak shown by iCIEF were (8.70��0.01),(8.26��0.01) and (8.85��0.01). The concentrations of polysorbate 20 were (0.34��0.00),(0.35��0.00) and (0.35��0.01) ��g��mL-1, respectively. The glycan mapping analysis was relatively sensitive, and the percentage of fucosylated N linked glycan was less than 0.5%. CONCLUSION Up-to-date quality control methods for recombinant anti-EBOV mAbs are established in this study, which may be used to ensure the safety, effectiveness and quality controllability of the product. The methods can provide technical assists to Ebola outbreak and be a reference of the quality control of other domestic cocktail monoclonal antibody products.
���Ĳ�, ����, �ڴ���, �ŷ�, ������, ����, ��ΰ, �߿�. ���鿹��������������¡�����ʿط����Ľ���[J]. �й�ҩѧ��־, 2016, 51(1): 46-51.
WANG Wen-bo, WANG Lan, YU Chuan-fei, ZHANG Feng, LIU Chun-yu, LI Meng, CHEN Wei, GAO Kai. Development of Quality Control Methods of Recombinant Anti-EBOV Antibodies. Chinese Pharmaceutical Journal, 2016, 51(1): 46-51.
NA W, PARK N, YEOM M, et al. Ebola outbreak in Western Africa 2014: What is going on with Ebola virus?. Clin Exp Vaccine Res,2014,4(1): 17-22.
QIU X, WONG G, AUDET J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature,2014,514(7520): 47-53.
LIU S D, CHALOUNI C, YOUNG J C, et al. Afucosylated antibodies increase activation of FcgammaRIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol Res,2015,3(2): 173-183.
KRAMSKI M, STRATOV I, KENT S J. The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. Aids,2015,29(2): 137-144.
ANDERSON C L, WANG Y, RUSTANDI R R. Applications of imaged capillary isoelectric focussing technique in development of biopharmaceutical glycoprotein-based products. Electrophoresis,2012,33(11):1538-1544.
LIU L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci,2015,104(6): 1866-1884.
SHI H H, GOUDAR C T. Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans. Biotechnol Bioeng,2014,111(10): 1907-1919.